Johnson & Johnson CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Blinded Dry Mouth Spray Crossover Study
- Conditions
- XerostomiaHead and Neck CancerXerostomia Following Radiotherapy
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jonas Johnson
- Target Recruit Count
- 129
- Registration Number
- NCT04608773
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
- Conditions
- Oral Pharyngeal CancerDysphagia
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Jonas Johnson
- Target Recruit Count
- 26
- Registration Number
- NCT02564887
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
News
PolyModels Hub Raises €7.9M Series A to Transform Biopharma Process Development with AI-Driven Platform
PolyModels Hub secured €7.9 million in Series A funding led by Molten Ventures to advance its ModelFlow platform for pharmaceutical process development.
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Strengthen Oncology Pipeline
Johnson & Johnson announced the acquisition of Halda Therapeutics for $3.05 billion in cash to expand its oncology portfolio with oral, targeted therapies for solid tumors.
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Strengthen Cancer Pipeline
Johnson & Johnson announced the acquisition of Halda Therapeutics for $3.05 billion in cash to enhance its oncology portfolio with novel oral cancer therapies.
Bristol Myers Squibb and J&J Halt Phase 3 Trial of Blood Thinner Milvexian in Acute Coronary Syndrome
Bristol Myers Squibb and Johnson & Johnson discontinued the Phase 3 Librexia ACS trial of milvexian after an interim analysis showed the drug was unlikely to meet its primary efficacy endpoint.
Legend Biotech Opens 31,000-Square-Foot R&D Facility in Philadelphia to Advance CAR-T Cell Therapy Innovation
Legend Biotech officially opened a new 31,000-square-foot research and development facility in Philadelphia to support its expanding pipeline of next-generation cell therapies.
Day One Biopharmaceuticals Acquires Mersana Therapeutics for $129M, Targeting Rare Cancer Treatment
Day One Biopharmaceuticals announced the acquisition of Mersana Therapeutics for $129 million upfront, with potential additional payments of $156 million tied to development milestones.
FDA Approves Kura Oncology's Komzifti for NPM1-Mutated AML with Competitive Safety Advantage
The FDA approved Kura Oncology's once-daily pill Komzifti (ziftomenib) for treating relapsed/refractory acute myeloid leukemia with NPM1 mutations, affecting about 30% of AML cases.
Scripta Therapeutics Raises $12M to Target Transcription Factors for Disease-Modifying Therapies
Oxford-based Scripta Therapeutics emerged from stealth with a $12M seed round to pioneer a biology-first approach to drug discovery targeting transcription factors.
XOMA Royalty Reports Strong Q3 2025 Results with Multiple Strategic Acquisitions and Key Pipeline Milestones
XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties.
Genmab Reports Strong Q3 2025 Results with Key Pipeline Advances and $8 Billion Merus Acquisition
Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.